Department of Pharmacokinetics and Clinical Pharmacy, Faculty of Pharmacy, University of Belgrade, 11000 Belgrade, Serbia.
Clinic for Gastroenterology and Hepatology, Clinical Centre of Serbia, School of Medicine, University of Belgrade, 11000 Belgrade, Serbia.
Medicina (Kaunas). 2019 Jun 3;55(6):243. doi: 10.3390/medicina55060243.
Data suggests that nearly 30% of the general population have steatosis and up to 5% of this population develops nonalcoholic steatohepatitis (NASH). Liver biopsy is still considered to be the gold standard for the diagnosis of NASH. Great effort is being made toward the identification of sensitive diagnostic tests that do not involve invasive procedures to address a common concern in patients with the nonalcoholic fatty liver disease-whether they have NASH or simple steatosis. We aimed to investigate the independent predictors and develop a non-invasive, easy-to-perform, low-cost set of parameters that may be used in clinical practice to differentiate simple steatosis from NASH. Methods: А cross-sectional study of nonalcoholic fatty liver disease (NAFLD) patients divided into two groups: group I-simple steatosis (SS) and group II-biopsy-proven NASH. Strict inclusion criteria and stepwise analysis allowed the evaluation of a vast number of measured/estimated parameters. One hundred and eleven patients were included-82 with simple steatosis and 29 with biopsy-proven NASH. The probability of NASH was the highest when homeostatic model assessment of insulin resistance (HOMA-IR) was above 2.5, uric acid above 380 µmol/L, ferritin above 100 µg/L and ALT above 45 U/L. An acronym of using first letters was created and named the HUFA index. This combined model resulted in an area under the receiver operator characteristic curve (AUROC) of 0.94, provided sensitivity, specificity, positive predictive value and a negative predictive value for NASH of 70.3%, 95.1%, 83.1% and 90.0%, respectively. : We suggest a simple non-invasive predictive index HUFA that encompasses four easily available parameters (HOMA-IR, uric acid, ferritin and ALT) to identify patients with NASH, which may reduce the need for a liver biopsy on a routine basis in patients with NAFLD.
数据表明,近 30%的普通人群患有脂肪变性,多达 5%的人群发展为非酒精性脂肪性肝炎(NASH)。肝活检仍然被认为是诊断 NASH 的金标准。人们正在努力寻找敏感的诊断测试方法,这些方法不涉及侵入性程序,以解决非酒精性脂肪肝患者的一个共同问题——他们是否患有 NASH 或单纯性脂肪变性。我们旨在研究独立预测因子,并开发一组非侵入性、易于执行、低成本的参数,这些参数可在临床实践中用于区分单纯性脂肪变性和 NASH。
一项非酒精性脂肪性肝病(NAFLD)患者的横断面研究,分为两组:I 组单纯性脂肪变性(SS)和 II 组活检证实的 NASH。严格的纳入标准和逐步分析允许评估大量测量/估计的参数。共纳入 111 例患者,其中 82 例为单纯性脂肪变性,29 例为活检证实的 NASH。当稳态模型评估的胰岛素抵抗(HOMA-IR)高于 2.5、尿酸高于 380μmol/L、铁蛋白高于 100μg/L 和 ALT 高于 45U/L 时,NASH 的可能性最高。创建了一个首字母缩写词,并将其命名为 HUFA 指数。该联合模型的受试者工作特征曲线下面积(AUROC)为 0.94,为 NASH 提供了 70.3%、95.1%、83.1%和 90.0%的敏感性、特异性、阳性预测值和阴性预测值。
我们建议使用 HUFA 这一简单的非侵入性预测指数,该指数包含四个易于获得的参数(HOMA-IR、尿酸、铁蛋白和 ALT)来识别患有 NASH 的患者,这可能会减少非酒精性脂肪性肝病患者常规肝活检的需求。